Xiaoyan Wang1, Yajun Lian2, Xin Wen3, Jing Guo2, Zhiping Wang2, Sheng Jiang2, Yaodong Hu2. 1. Department of Ultrasound, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China. 2. Department of Cardiology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China. 3. Department of Pharmacy, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China.
Abstract
OBJECTIVE: This study aimed to explore the role of miR-126 in coronary artery disease (CAD) patients and the potential gene targets of miR-126 in atherosclerosis. METHODOLOGY: A total of 60 CAD patients and 25 healthy control subjects were recruited in this study. Among the 60 CAD patients, 18 cases were diagnosed of stable angina pectoris (SAP), 20 were diagnosed of unstable angina pectoris (UAP) and 22 were diagnosed of acute myocardial infarction (AMI). Plasma miR-126 levels from both groups of participants were analyzed by real-time quantitative PCR. ELISA was used to measure plasma level of placenta growth factor (PLGF). RESULTS: The results showed that the miR-126 expression was significantly down-regulated in the circulation of CAD patients compared with control subjects (P<0.01). Plasma PLGF level was significantly upregulated in patients with unstable angina pectoris and acute myocardial infarction (AMI) compared with controls (both P<0.01) the miR-126 expression in AMI was significantly associated with PLGF. CONCLUSION: miR-126 may serve as a novel biomarker for CAD.
OBJECTIVE: This study aimed to explore the role of miR-126 in coronary artery disease (CAD) patients and the potential gene targets of miR-126 in atherosclerosis. METHODOLOGY: A total of 60 CAD patients and 25 healthy control subjects were recruited in this study. Among the 60 CAD patients, 18 cases were diagnosed of stable angina pectoris (SAP), 20 were diagnosed of unstable angina pectoris (UAP) and 22 were diagnosed of acute myocardial infarction (AMI). Plasma miR-126 levels from both groups of participants were analyzed by real-time quantitative PCR. ELISA was used to measure plasma level of placenta growth factor (PLGF). RESULTS: The results showed that the miR-126 expression was significantly down-regulated in the circulation of CAD patients compared with control subjects (P<0.01). Plasma PLGF level was significantly upregulated in patients with unstable angina pectoris and acute myocardial infarction (AMI) compared with controls (both P<0.01) the miR-126 expression in AMI was significantly associated with PLGF. CONCLUSION:miR-126 may serve as a novel biomarker for CAD.
Authors: Maria Angelica Cortez; Carlos Bueso-Ramos; Jana Ferdin; Gabriel Lopez-Berestein; Anil K Sood; George A Calin Journal: Nat Rev Clin Oncol Date: 2011-06-07 Impact factor: 66.675
Authors: X J Wei; M Han; F Y Yang; G C Wei; Z G Liang; H Yao; C W Ji; R S Xie; C L Gong; Y Tian Journal: Braz J Med Biol Res Date: 2015-08-25 Impact factor: 2.590
Authors: Valentina Bollati; Laura Angelici; Giovanna Rizzo; Laura Pergoli; Federica Rota; Mirjam Hoxha; Francesco Nordio; Matteo Bonzini; Letizia Tarantini; Laura Cantone; Angela C Pesatori; Pietro Apostoli; Andrea A Baccarelli; Pier Alberto Bertazzi Journal: J Appl Toxicol Date: 2014-02-07 Impact factor: 3.446
Authors: Emma L Solly; Catherine G Dimasi; Christina A Bursill; Peter J Psaltis; Joanne T M Tan Journal: J Clin Med Date: 2019-12-13 Impact factor: 4.241
Authors: Elena Inzaghi; Anna Kistner; Daniela Germani; Annalisa Deodati; Mireille Vanpee; Lena Legnevall; Katarina Berinder; Stefano Cianfarani Journal: PLoS One Date: 2020-01-24 Impact factor: 3.240